Carbapenems against Mycobacterium tuberculosis: A review of the evidence

D. Jaganath, G. Lamichhane, M. Shah

Research output: Research - peer-reviewReview article

Abstract

Carbapenems, a more recent β-lactam class, represent a unique anti-tuberculosis option, as emerging evidence demonstrates that they target the Mycobacterium tuberculosis cell wall and β-lactamase. This provides a potentially new agent against M. tuberculosis, in particular for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), where options are limited. In this review, we examine the current evidence on the activity of carbapenems against M. tuberculosis. The predominance of work is in vitro, and suggests that carbapenems kill M. tuberculosis at least in the active phase, with possible greater potency with the addition of a β-lactamase inhibitor. The few in vivo and clinical studies suggest that there are benefits and that they are generally tolerated, although the variability in duration, dosing, and background regimen and lack of pharmacokinetic analyses limit interpretation of efficacy. We outline further areas of research to better understand the role of carbapenems to add a needed new agent to the treatment of MDR- and XDRTB.

LanguageEnglish (US)
Pages1436-1447
Number of pages12
JournalInternational Journal of Tuberculosis and Lung Disease
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Carbapenems
Mycobacterium tuberculosis
Tuberculosis
Extensively Drug-Resistant Tuberculosis
beta-Lactams
beta-Lactamases
Cell Wall
Pharmacokinetics
Research
In Vitro Techniques
Clinical Studies
beta-Lactamase Inhibitors
Agent M

Keywords

  • Anti-tuberculosis
  • Antibiotics
  • Extensively drug-resistant tuberculosis
  • Group D
  • Multidrug-resistant tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Carbapenems against Mycobacterium tuberculosis : A review of the evidence. / Jaganath, D.; Lamichhane, G.; Shah, M.

In: International Journal of Tuberculosis and Lung Disease, Vol. 20, No. 11, 01.11.2016, p. 1436-1447.

Research output: Research - peer-reviewReview article

@article{88b1debef7a7401cb754555ef16a9014,
title = "Carbapenems against Mycobacterium tuberculosis: A review of the evidence",
abstract = "Carbapenems, a more recent β-lactam class, represent a unique anti-tuberculosis option, as emerging evidence demonstrates that they target the Mycobacterium tuberculosis cell wall and β-lactamase. This provides a potentially new agent against M. tuberculosis, in particular for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), where options are limited. In this review, we examine the current evidence on the activity of carbapenems against M. tuberculosis. The predominance of work is in vitro, and suggests that carbapenems kill M. tuberculosis at least in the active phase, with possible greater potency with the addition of a β-lactamase inhibitor. The few in vivo and clinical studies suggest that there are benefits and that they are generally tolerated, although the variability in duration, dosing, and background regimen and lack of pharmacokinetic analyses limit interpretation of efficacy. We outline further areas of research to better understand the role of carbapenems to add a needed new agent to the treatment of MDR- and XDRTB.",
keywords = "Anti-tuberculosis, Antibiotics, Extensively drug-resistant tuberculosis, Group D, Multidrug-resistant tuberculosis",
author = "D. Jaganath and G. Lamichhane and M. Shah",
year = "2016",
month = "11",
doi = "10.5588/ijtld.16.0498",
volume = "20",
pages = "1436--1447",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "11",

}

TY - JOUR

T1 - Carbapenems against Mycobacterium tuberculosis

T2 - International Journal of Tuberculosis and Lung Disease

AU - Jaganath,D.

AU - Lamichhane,G.

AU - Shah,M.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Carbapenems, a more recent β-lactam class, represent a unique anti-tuberculosis option, as emerging evidence demonstrates that they target the Mycobacterium tuberculosis cell wall and β-lactamase. This provides a potentially new agent against M. tuberculosis, in particular for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), where options are limited. In this review, we examine the current evidence on the activity of carbapenems against M. tuberculosis. The predominance of work is in vitro, and suggests that carbapenems kill M. tuberculosis at least in the active phase, with possible greater potency with the addition of a β-lactamase inhibitor. The few in vivo and clinical studies suggest that there are benefits and that they are generally tolerated, although the variability in duration, dosing, and background regimen and lack of pharmacokinetic analyses limit interpretation of efficacy. We outline further areas of research to better understand the role of carbapenems to add a needed new agent to the treatment of MDR- and XDRTB.

AB - Carbapenems, a more recent β-lactam class, represent a unique anti-tuberculosis option, as emerging evidence demonstrates that they target the Mycobacterium tuberculosis cell wall and β-lactamase. This provides a potentially new agent against M. tuberculosis, in particular for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), where options are limited. In this review, we examine the current evidence on the activity of carbapenems against M. tuberculosis. The predominance of work is in vitro, and suggests that carbapenems kill M. tuberculosis at least in the active phase, with possible greater potency with the addition of a β-lactamase inhibitor. The few in vivo and clinical studies suggest that there are benefits and that they are generally tolerated, although the variability in duration, dosing, and background regimen and lack of pharmacokinetic analyses limit interpretation of efficacy. We outline further areas of research to better understand the role of carbapenems to add a needed new agent to the treatment of MDR- and XDRTB.

KW - Anti-tuberculosis

KW - Antibiotics

KW - Extensively drug-resistant tuberculosis

KW - Group D

KW - Multidrug-resistant tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84992504914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992504914&partnerID=8YFLogxK

U2 - 10.5588/ijtld.16.0498

DO - 10.5588/ijtld.16.0498

M3 - Review article

VL - 20

SP - 1436

EP - 1447

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 11

ER -